Search results
28 cze 2024 · Patients treated with IST need life-long monitoring by BM biopsies with cytogenetics and NGS to allow timely intervention with allogeneic HCT for MN. Even so, allogeneic HCT for monosomy 7 AML, for example, provides a 2-year leukemia-free survival of only 28.5% and a 2-year OS of 34.9% [ 18 ].
5 sty 2022 · Aplastic anemia is the prototype of the bone marrow failure syndromes that are characterized by hypocellular marrow and pancytopenia, and severe aplastic anemia is fatal if untreated. 1...
Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a...
1 kwi 2019 · Although a rare disease, aplastic anemia should be distinguished from other cases of pancytopenia, and patients should receive the best treatment available based on their age, and the existence of a matched sibling donor.
26 lut 2024 · The treatment of aplastic anemia (AA) has significantly advanced in the last 50 years, evolving from a fatal condition to one where survival rates now exceed 80–85%.
4 gru 2023 · This topic reviews the treatment and prognosis of AA in adults. For adults, the evaluation of pancytopenia; pathogenesis, clinical manifestations, and diagnosis of AA; and hematopoietic cell transplantation for AA are discussed separately.
1 sie 2024 · For patients aged <40 years, the estimated OS after 3 years was 94.6 ± 2.7% in the IST + EPAG group and 82.9 ± 3.4% in the Haplo-HSCT group (P = 0.013) (Fig. 2c). The estimated FFS after 3...
